Age-related macular degeneration (AMD), the leading cause of vision loss affecting over 200 million people globally, results from degeneration of retinal pigment epithelial (RPE) cells, which are vital for retinal health. In ageing retina, low oxygen (hypoxia) occurs. This project explores how hypoxia affects Ca2+ signalling, which cells use to perform tasks like clearing waste and moving nutrients in retina. Using stem cell technology and a novel microscale hypoxia device, we will study how hypoxia contributes to AMD. The research will be employed at Tampere University, which provides advanced research facilities. By uncovering mechanisms and identifying therapeutic targets, the research aims to advance gene therapies, improve understanding or retinal degeneration, and contribute to preventing blindness, a major global health challenge.

2026

2030